ArticleJournal of substance abuse treatment2020
Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities.
Article in Journal of substance abuse treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- COVID-19 isolation and recovery sites evaluation: Lessons learned for systems innovation.Canadian journal of public health = Revue canadienne de sante publique · 2025Article
- A qualitative exploration of harm reduction in practice by street-based peer outreach workers.Harm reduction journal · 2024Article
- Perspectives and recommendations of opioid overdose survivors experiencing unsheltered homelessness on housing, overdose, and substance use treatment in Boston, MA.The International journal on drug policy · 2023Article
- Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness.Drug and alcohol dependence · 2022Article
- Managed alcohol: one community's innovative response to risk management during COVID-19.Harm reduction journal · 2021Article
- Strategies Adopted by Addiction Facilities during the Coronavirus Pandemic to Support Treatment for Individuals in Recovery or Struggling with a Substance Use Disorder: A Scoping Review.International journal of environmental research and public health · 2021Article
- Impact on Mental Well-Being and Resilience of Patients with Multiple Chronic Conditions in Different Periods during the Coronavirus Disease 2019 Outbreak in Taiwan.Healthcare (Basel, Switzerland) · 2021Article
- Understanding the impact of the SARS-COV-2 pandemic on hospitalized patients with substance use disorder.PloS one · 2021Article
- Why Timing Matters in Alcohol Use Disorder Recovery.The American journal of psychiatry · 2020Article
- Isolation, Solitude and Social Distancing for People Who Use Drugs: An Ethnographic Perspective.Frontiers in psychiatry · 2020Article
- Xylazine-associated Wounds: Clinical Experience From a Low-barrier Wound Care Clinic in Philadelphia.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In response to the novel coronavirus 2019 (Covid-19) pandemic, many people experiencing homelessness and substance use disorders entered respite and recuperation facilities for care and to isolate and prevent subsequent SARS-CoV-2 transmission. However, because drug use was officially prohibited in these facilities, we observed people who use substances leaving isolation temporarily or prematurely. The initial Covid-19 surge magnified the need for harm reduction access for those who use substances to ensure their safety and well-being and that of their local communities. In this commentary, we argue that expanding harm reduction access is crucial for subsequent waves of SARS-CoV-2 infection and also for patients who use substances and are hospitalized for other reasons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.